Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region.
Al Tahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif A, Deleu D, Esmat K, Giampaolo D, Freedman MS, Gwilt M, Hosny H, Inshasi JS, Aljumah M, Khalifa A, Pakdaman H, Szólics M, Yamout BI, Sahraian MA, Zakaria MF. Al Tahan AM, et al. Among authors: pakdaman h. Int J Neurosci. 2014 Sep;124(9):635-41. doi: 10.3109/00207454.2013.865620. Epub 2013 Dec 18. Int J Neurosci. 2014. PMID: 24228830 Review.
Biosimilars: opinion of an expert panel in the Middle East.
Bohlega S, Al-Shammri S, Al Sharoqi I, Dahdaleh M, Gebeily S, Inshasi J, Khalifa A, Pakdaman H, Szólics M, Yamout B. Bohlega S, et al. Among authors: pakdaman h. Curr Med Res Opin. 2008 Oct;24(10):2897-903. doi: 10.1185/03007990802381554. Epub 2008 Sep 2. Curr Med Res Opin. 2008. PMID: 18768104 Review.
Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.
Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M; International Working Group for Treatment Optimization in MS. Goodin DS, et al. Among authors: pakdaman h. Curr Med Res Opin. 2007 Nov;23(11):2823-32. doi: 10.1185/03007x233007. Curr Med Res Opin. 2007. PMID: 17908370 Review.
Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Tabassi A, Ashrafi F, Ghaffarpor M, Sharifi S, Delavar Kasmae H, Assarzadegan F, Arabahmadi M, Behnam B. Pakdaman H, et al. Int J Neurosci. 2017 Jun;127(6):501-507. doi: 10.1080/00207454.2016.1198793. Epub 2016 Jul 19. Int J Neurosci. 2017. PMID: 27279451 Clinical Trial.
Old findings in multiple sclerosis but a new application.
Harandi AA, Sahraiyan MA, Gharagozli K, Pakdaman H, Kalanie H. Harandi AA, et al. Among authors: pakdaman h. Clin Neurol Neurosurg. 2012 May;114(4):411. doi: 10.1016/j.clineuro.2011.11.014. Epub 2011 Nov 30. Clin Neurol Neurosurg. 2012. PMID: 22134103 No abstract available.
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial.
Pakdaman H, Harandi AA, Hatamian H, Tabatabae M, Delavar Kasmaei H, Ghassemi A, Gharagozli K, Ashrafi F, Emami Naeini P, Tavakolian M, Shahin D. Pakdaman H, et al. Dement Geriatr Cogn Dis Extra. 2015 Mar 7;5(1):96-106. doi: 10.1159/000375295. eCollection 2015 Jan-Apr. Dement Geriatr Cogn Dis Extra. 2015. PMID: 25873931 Free PMC article.
Vagus nerve stimulation in drug-resistant epilepsy: the efficacy and adverse effects in a 5-year follow-up study in Iran.
Pakdaman H, Amini Harandi A, Abbasi M, Karimi M, Arami MA, Mosavi SA, Haddadian K, Rezaei O, Sadeghi S, Sharifi G, Gharagozli K, Bahrami P, Ashrafi F, Kasmae HD, Ghassemi A, Arabahmadi M, Behnam B. Pakdaman H, et al. Neurol Sci. 2016 Nov;37(11):1773-1778. doi: 10.1007/s10072-016-2661-3. Epub 2016 Jul 11. Neurol Sci. 2016. PMID: 27401807
64 results